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Poster Presentations: Wednesday, July 17, 2019 S1535a CR of 38.1/1000 person-years and the other 50%, CDR ¼ 0.5
(70% with sum of boxes scores1, CR¼ 145.4/1000 person-years
and 30% > 1, CR ¼ 216.8/1000 person-years). CR was 91.3/1000
person-years on average. In the multivariate analysis, when
compared with those with CDR ¼ 0, the hazard ratio of those
with CDR ¼ 0.5 was 3.82; and for those with CDR ¼ 0.5 and
sum of boxes scores >1, 5.69. Conclusions: Conversion rate to de-
mentia was significantly higher among those with CDR ¼ 0.5 and
even higher for those whose sum of boxes scores was >1. There-
fore, CDRwas able to predict which individuals had a higher likeli-
hood of converting to dementia.P4-564 SHORT-TERM OUTCOMES OFARANDOMIZED CONTROLLED TRIAL OF
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Background: Emerging literature suggests that disclosing amyloid
PET results to cognitively normal adults may have no clinically
meaningful effect on psychological well-being. However, revealing
these same results in the context of existing cognitive decline may
carry very different implications. We examined the short-term ef-
fects of amyloid imaging results disclosure on patients with MCI
and their caregivers. Methods: Our randomized controlled trial of
162 individuals (n¼81 patients with MCI; n¼81 caregivers)
included 41 patient/caregiver dyads allocated to a scan group and
40 to a comparison condition (an MCI education session). Assess-
ments of MCI/AD knowledge, perceived understanding of MCI,
self-efficacy for coping with MCI, and mood were conducted at
baseline and 4 weeks post-results disclosure (scan group) or post-
MCI education session (comparison group). We hypothesized
that, irrespective of scan results, having the opportunity to learn
more about the potential etiology of cognitive symptoms would
improve patients’ and caregivers’ overall understanding of, and
self-efficacy for coping with, MCI. Results: Objective knowledge
of MCI/AD increased from baseline to week-4 in both the scan
and comparison groups among caregivers (FT¼0.05, p¼0.002),
but not patients. Perceived understanding of MCI decreased in
the subgroup of scan patients who were amyloid negative
(FG3T¼3.37, p¼0.041), and was unchanged among other partici-
pants. As compared to baseline, caregivers in the scan group re-
ported decreased self-efficacy for coping with their relatives’
MCI (mean difference¼-12.4764.4; p<0.01); a finding most pro-
nounced among caregivers of amyloid positive individuals (mean
difference¼-14.8367.02; p<0.05). Patients in both the scan and
comparison groups reported increased depressive symptoms over
time (FT¼6.42, p¼0.014), yet overall mood symptoms (depression
+ anxiety) decreased by 47% from baseline to week-4 within the
subgroup of amyloid negative scan patients (p<0.01). Post-disclo-
sure impact of event scores (IGT-AD) were significantly higher in
both patients (27.2563.58 vs. 9.1565.52; p<0.001) and caregivers
(2263.91 vs. 6.7561.54; p¼0.001) of amyloid positive patients as
compared to amyloid negative patients. Conclusions: Amyloid
negative patients showed improved mood but greater uncertaintyabout their MCI at follow-up. Significant test-related distress was
present in amyloid positive patients and caregivers, with caregivers
feeling less able to cope with MCI after learning that it is likely a
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(AD) and other dementias. We examined if intact performance on
brief cognitive and odor identification tests predicts lack of transi-
tion to dementia. Methods: In an urban community cohort, 1,037
older adults without dementia completed the 40-item University
of Pennsylvania Smell Identification Test (UPSIT), which includes
the 12-item Brief Smell Identification Test (BSIT). Of 749 partici-
pants who were followed for up to 4 years, data for 711 participants
without anosmia were analyzed. We evaluated the predictive utility
of the BSIT and the Blessed Orientation Memory Concentration
Test (BOMC) for the transition to dementia, AD and cognitive
decline. Results: In covariate-adjusted survival analyses, impair-
ment on BOMC (HR 5.42, 95% CI 3.26-9.01, p<.0001) and
BSIT (HR 2.11, 95% CI 1.05-4.24, p<.04) each significantly pre-
dicted dementia, and AD. Among participants with intact olfactory
(BSIT  11/12 correct) and cognitive (BOMC  5/28 incorrect)
ability, 3.4% (4/117) transitioned to dementia with no transitions
in the 70-75 and 81-83 years age group quartiles. In covariate-
adjusted logistic regression analyses, impaired BSIT performance
was associated with cognitive decline (p<.006), but BOMC was
not (p¼0.26). Conclusions: Brief assessments of odor identification
and global cognition can identify individuals who rarely transition
to dementia, thereby avoiding unnecessary diagnostic investiga-
tion. Identifying these individuals may have potential utility in
the decision to exclude patients in treatment trials of cognitively
impaired or at-risk patients, or prevention trials in cognitively intact
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